We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Strategic Partnership Launches Molecular Assay for Breast Cancer

By LabMedica International staff writers
Posted on 22 Dec 2010
A real-time polymerase chain reaction (RT-PCR) based panel has been optimized for analysis of ribonucleic acid (RNA) in suspected cancerous tissue samples.

The assay is a breast cancer-segregation panel, which measures 96 genes identified in a proprietary meta-analysis of cancer genomic data from more than 5,000 clinical samples. More...
The RNA is extracted from formalin-fixed, paraffin-embedded (FFPE) tissues.

AltheaDx, Inc., (San Diego, CA, USA) will process and analyze samples in its San Diego-based Clinical Laboratory Improvement Amendments/ Good Laboratory Practice (CLIA/GLP) laboratory. The other partner, Compendia Bioscience, (Ann Arbor, MI, USA), will manage downstream data analysis and statistical correlation to patient outcomes in clinical trials. AltheaDx has facilitated the clinical utilization of biomarkers through validation and clinical sample testing under GLP and/or CLIA. The Breast Cancer Segregation Panel is now available to aid clinical diagnosis.

Francois Ferre, PhD, AltheaDx's cofounder and CEO, said, "Compendia Bioscience is the recognized leader in translating cancer genomic data into meaningful information related to patient outcomes in clinical trials. Compendia's powerful bioinformatics platform is providing highly valuable content around which we can develop predictive tests for our other partners." Daniel R. Rhodes, PhD, cofounder and CEO of Compendia Bioscience added, "AltheaDx has been a pioneering developer of PCR-based assays in clinical settings since its inception with very deep technical capabilities in genetic analysis."

The two companies will jointly create novel products and services focused on cancer biomarker discovery and subsequent development of tests that predict patient outcomes in clinical trials. Under the terms of the partnership, the companies plan to develop Segregation Panels for other cancer types. The next assay, the Colorectal Cancer Segregation Panel, will be released in 2011.

Related Links:

AltheaDx
Compendia Bioscience




New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.